NO20092370L - Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon - Google Patents
Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanonInfo
- Publication number
- NO20092370L NO20092370L NO20092370A NO20092370A NO20092370L NO 20092370 L NO20092370 L NO 20092370L NO 20092370 A NO20092370 A NO 20092370A NO 20092370 A NO20092370 A NO 20092370A NO 20092370 L NO20092370 L NO 20092370L
- Authority
- NO
- Norway
- Prior art keywords
- pyridin
- chlorophenyl
- docket number
- font
- triazol
- Prior art date
Links
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 (2-chlorophenyl) - [2- (2 -hydroxy-2-pyridin-4-yl-vinyl) pyridin-3-yl] Chemical class 0.000 abstract 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 abstract 1
- 241000764238 Isis Species 0.000 abstract 1
- BCYBZAQWIMJEOI-UHFFFAOYSA-N benzoic acid (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-ylethenyl)pyridin-3-yl]methanone Chemical compound OC(=O)C1=CC=CC=C1.C=1C=NC=CC=1C(O)=CC1=NC=CC=C1C(=O)C1=CC=CC=C1Cl BCYBZAQWIMJEOI-UHFFFAOYSA-N 0.000 abstract 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 abstract 1
- 230000008676 import Effects 0.000 abstract 1
- 238000012739 integrated shape imaging system Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87085106P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/086319 WO2008079600A1 (en) | 2006-12-20 | 2007-12-04 | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092370L true NO20092370L (no) | 2009-09-16 |
Family
ID=39273082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092370A NO20092370L (no) | 2006-12-20 | 2009-06-22 | Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8772496B2 (pt) |
| EP (1) | EP2121610B1 (pt) |
| JP (1) | JP5443168B2 (pt) |
| KR (1) | KR20090081028A (pt) |
| CN (1) | CN101568523A (pt) |
| AU (1) | AU2007337255A1 (pt) |
| BR (1) | BRPI0721069A2 (pt) |
| CA (1) | CA2671770C (pt) |
| DK (1) | DK2121610T3 (pt) |
| EA (1) | EA200970604A1 (pt) |
| EC (1) | ECSP099441A (pt) |
| ES (1) | ES2471990T3 (pt) |
| HR (1) | HRP20140613T1 (pt) |
| IL (1) | IL198775B (pt) |
| MX (1) | MX2009006636A (pt) |
| NO (1) | NO20092370L (pt) |
| PL (1) | PL2121610T3 (pt) |
| PT (1) | PT2121610E (pt) |
| RS (1) | RS53386B (pt) |
| SI (1) | SI2121610T1 (pt) |
| WO (1) | WO2008079600A1 (pt) |
| ZA (1) | ZA200903578B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0721069A2 (pt) * | 2006-12-20 | 2014-02-04 | Lilly Co Eli | Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| AU2018331267B2 (en) | 2017-09-13 | 2024-03-07 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| CN119074729A (zh) * | 2017-11-17 | 2024-12-06 | 万达制药公司 | 使用川地匹坦治疗胃肠疾病的方法 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| JP7791832B2 (ja) | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| BRPI0415010B8 (pt) * | 2003-10-24 | 2021-05-25 | Lilly Co Eli | formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| BRPI0721069A2 (pt) * | 2006-12-20 | 2014-02-04 | Lilly Co Eli | Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona |
-
2007
- 2007-12-04 BR BRPI0721069-8A patent/BRPI0721069A2/pt not_active Application Discontinuation
- 2007-12-04 ES ES07865137.9T patent/ES2471990T3/es active Active
- 2007-12-04 DK DK07865137.9T patent/DK2121610T3/da active
- 2007-12-04 CN CNA2007800466993A patent/CN101568523A/zh active Pending
- 2007-12-04 HR HRP20140613TT patent/HRP20140613T1/hr unknown
- 2007-12-04 US US12/515,794 patent/US8772496B2/en active Active
- 2007-12-04 JP JP2009543027A patent/JP5443168B2/ja active Active
- 2007-12-04 CA CA2671770A patent/CA2671770C/en active Active
- 2007-12-04 PL PL07865137T patent/PL2121610T3/pl unknown
- 2007-12-04 MX MX2009006636A patent/MX2009006636A/es active IP Right Grant
- 2007-12-04 WO PCT/US2007/086319 patent/WO2008079600A1/en not_active Ceased
- 2007-12-04 PT PT78651379T patent/PT2121610E/pt unknown
- 2007-12-04 EA EA200970604A patent/EA200970604A1/ru unknown
- 2007-12-04 SI SI200731483T patent/SI2121610T1/sl unknown
- 2007-12-04 EP EP07865137.9A patent/EP2121610B1/en active Active
- 2007-12-04 KR KR1020097012894A patent/KR20090081028A/ko not_active Ceased
- 2007-12-04 AU AU2007337255A patent/AU2007337255A1/en not_active Abandoned
- 2007-12-04 RS RS20140349A patent/RS53386B/sr unknown
-
2009
- 2009-05-14 IL IL198775A patent/IL198775B/en active IP Right Grant
- 2009-05-22 ZA ZA200903578A patent/ZA200903578B/xx unknown
- 2009-06-17 EC EC2009009441A patent/ECSP099441A/es unknown
- 2009-06-22 NO NO20092370A patent/NO20092370L/no not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/227,857 patent/US20140206877A1/en not_active Abandoned
-
2015
- 2015-11-10 US US14/937,051 patent/US9708291B2/en active Active
-
2017
- 2017-06-15 US US15/623,550 patent/US10035787B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2121610T1 (sl) | 2014-08-29 |
| MX2009006636A (es) | 2009-06-30 |
| JP2010513546A (ja) | 2010-04-30 |
| US10035787B2 (en) | 2018-07-31 |
| US9708291B2 (en) | 2017-07-18 |
| CN101568523A (zh) | 2009-10-28 |
| RS53386B (sr) | 2014-10-31 |
| EP2121610B1 (en) | 2014-04-02 |
| DK2121610T3 (da) | 2014-06-30 |
| PT2121610E (pt) | 2014-06-25 |
| EP2121610A1 (en) | 2009-11-25 |
| EA200970604A1 (ru) | 2009-10-30 |
| ECSP099441A (es) | 2009-07-31 |
| BRPI0721069A2 (pt) | 2014-02-04 |
| US20160060250A1 (en) | 2016-03-03 |
| HRP20140613T1 (hr) | 2014-08-15 |
| WO2008079600A1 (en) | 2008-07-03 |
| US8772496B2 (en) | 2014-07-08 |
| IL198775A0 (en) | 2010-02-17 |
| KR20090081028A (ko) | 2009-07-27 |
| US20170283394A1 (en) | 2017-10-05 |
| PL2121610T3 (pl) | 2014-09-30 |
| CA2671770C (en) | 2015-09-15 |
| US20100056795A1 (en) | 2010-03-04 |
| ZA200903578B (en) | 2010-07-28 |
| AU2007337255A1 (en) | 2008-07-03 |
| IL198775B (en) | 2018-08-30 |
| CA2671770A1 (en) | 2008-07-03 |
| US20140206877A1 (en) | 2014-07-24 |
| JP5443168B2 (ja) | 2014-03-19 |
| ES2471990T3 (es) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092370L (no) | Nye intermeditater og fremgangsmate anvendelig i fremstillingen av {2-[1-(3,5-bis-tri-fluormetyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-klorfenyl)-metanon | |
| NZ594537A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| WO2008111441A1 (ja) | 医薬組成物 | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| JP2013514345A5 (pt) | ||
| WO2007081569A3 (en) | Cetp inhibitors | |
| JP2014507464A5 (pt) | ||
| WO2005037781A3 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| WO2012082815A3 (en) | Composition and method for reducing hydrate agglomeration | |
| MY147389A (en) | Phthalazinone derivative | |
| NZ601786A (en) | Novel compounds and compositions and methods of use | |
| PL2625175T3 (pl) | Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR | |
| DE60112933D1 (de) | N-phenyl-4-(4-pyridyl)-2-pyrimidinamine-derivate | |
| DE602006019788D1 (de) | Oximester-Fotoinitiatoren | |
| NZ581698A (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| PE20190345A1 (es) | Combinaciones de compuestos activos | |
| BR112012007069A2 (pt) | derivado de fenol | |
| MX2010003366A (es) | Derivados de piperidina y piperazina para el tratamiento de tumores. | |
| NO20083390L (no) | Piperaziner og piperidiner som mGluR5-forsterkere | |
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| UA109638C2 (uk) | Сполуки та спосіб зниження рівня сечової кислоти | |
| JP2011510055A5 (pt) | ||
| AR114965A2 (es) | Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina | |
| PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |